Clinical Trial Update: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating APG-2575 as a single agent or in combination with ibrutinib or rituximab in Waldenström macroglobulinemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• APG-2575
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Waldenstrom Macroglobulinemia | Phase 1 | Status: COMPLETED